Cancers · 2022 · 15 citations · 33 references
MedicineHematologyPharmacologyCancer PharmacologyHematologic OncologyHemostasisAnticoagulant TherapyAnticoagulation ManagementAnticoagulation TherapyThromboembolic DiseaseThrombosisThrombosis PreventionAnticoagulant BiomarkersCoagulation BiomarkersLow-molecular-weight Heparin TherapyRecurrent Venous ThromboembolismTherapeutic AnticoagulationThrombotic Risk AssessmentVenous Thromboembolism BiomarkersVenous Thromboembolism Recurrence
The most appropriate duration of anticoagulant treatment for cancer-associated venous thromboembolism (CAT) remains unclear. We have conducted a prospective multicenter study in CAT patients with more than 6 months of anticoagulant treatment to predict the risk of venous thromboembolism (VTE) recurrence after anticoagulation discontinuation. Blood samples were obtained when patients stopped the anticoagulation, at 21 days and at 90 days. In each sample we assessed different coagulation-related biomarkers: D-dimer (DD), high-sensitivity C-reactive protein (hs-CRP), P-selectin (PS), phospholipids, soluble tissue factor, factor VIII and the thrombin generation test. It was evaluated 325 CAT patients and 166 patients were included in the study, mean age 64 ± 17 years. VTE recurrence until 6 months after stopping anticoagulation treatment was 9.87% [95% confidence interval (CI): 6−15]. The biomarkers sub-distribution hazard ratios were 6.32 for ratio DD basal/DD 21 days > 2 (95% CI: 1.82−21.90), 6.36 for hs-CRP > 4.5 (95% CI: 1.73−23.40) and 5.58 for PS > 40 (95% CI: 1.46−21.30) after 21 days of stopping anticoagulation. This is the first study that has identified the DD ratio, hs-CRP and PS as potential biomarkers of VTE recurrence in cancer patients after the discontinuation of anticoagulation treatment. A risk-adapted strategy may allow the identification of the optimal time to withdraw the anticoagulation in each CAT patient.
33
Antithrombotic Therapy for VTE Disease
Clive Kearon, Elie A. Akl, Joseph Ornelas et al. · CHEST Journal · 2016 · 4.8K citations
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana, Nicole M. Kuderer, Eva Culakova et al. · Blood · 2008 · 2.2K citations · Full text
Medicine, Hematology, Oncology +14
Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis
Jeanet W. Blom · JAMA · 2005 · 2K citations
Medicine, Genetics, Hematology +14
Prognosis of Cancers Associated with Venous Thromboembolism
Henrik Toft Sørensen, Lene Mellemkjær, Jørgen H. Olsen et al. · New England Journal of Medicine · 2000 · 1.6K citations · Full text
Medicine, Hematology, Oncology +12